Holly Schachner
Hoofd Techniek/Wetenschap/O&O bij DoubleRainbow Biosciences, Inc.
Profiel
Holly Schachner is currently the Chief Medical Officer at DoubleRainbow Biosciences, Inc. She previously worked as the Lead Independent Director at Applied Molecular Transport, Inc. from 2021 to 2023, Senior Vice President-Clinical Science Therapeutic at MyoKardia, Inc. from 2020 to 2021, Head-Diabetes & Cardiovascular Business Unit at Sanofi SA from 2016 to 2019, and Chief Medical Officer-Global Specialty Medicine at Allergan Ltd.
(Ireland) from 2019 to 2020.
Dr. Schachner holds a doctorate degree from Stony Brook School and an undergraduate degree from the University of Michigan.
Actieve functies van Holly Schachner
| Bedrijven | Functie | Begin |
|---|---|---|
DoubleRainbow Biosciences, Inc.
 DoubleRainbow Biosciences, Inc. BiotechnologyHealth Technology DoubleRainbow Biosciences, Inc. engages in the development of transformative technologies. It explores essential natural ingredients that enhance daily experience and health through food, beverages, cosmetics, supplements, and other consumer products. The company was founded by Jing Ke Weng and Tian Xu and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | 01-08-2021 |
Eerdere bekende functies van Holly Schachner
| Bedrijven | Functie | Einde |
|---|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Directeur/Bestuurslid | 27-12-2023 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 01-04-2021 |
| ALLERGAN PLC | Corporate Officer/Principal | 01-07-2020 |
| Sanofi SA | Corporate Officer/Principal | 01-01-2019 |
Opleiding van Holly Schachner
| Stony Brook School | Doctorate Degree |
| University of Michigan | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
| Sanofi SA | Health Technology |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
DoubleRainbow Biosciences, Inc.
DoubleRainbow Biosciences, Inc. BiotechnologyHealth Technology DoubleRainbow Biosciences, Inc. engages in the development of transformative technologies. It explores essential natural ingredients that enhance daily experience and health through food, beverages, cosmetics, supplements, and other consumer products. The company was founded by Jing Ke Weng and Tian Xu and is headquartered in Cambridge, MA. | Health Technology |